Defining AI And Working With Pharma, Mind The Byte CEO Weighs In
On the sidelines of the recent BIO-Europe Spring partnering meeting in Amsterdam, Alfons Nonell-Canals, CEO of artificial intelligence company Mind the Byte, chats with Scrip about the common misconceptions of AI in drug development. He also highlights how the company, which is based in Barcelona, is working with pharma and biotech partners.
You may also be interested in...
Diversity in all forms is critical to innovation in health care, says AstraZeneca’s chief medical officer, Ann Taylor. In an exclusive interview, she talks about the company’s work in mentoring and education, and why tackling issues around diversity and inclusion must be driven by the C-suite alongside community initiatives.
A selection of articles you might have missed from October 2020, including exclusive interviews with industry leaders and a deeper dive into the Femtech market.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.